Managing the risk of osteoporosis in women with a history of early breast cancer

ONCOLOGY

Volumn 18, Issue 11, 2004, Pages 1385-1393

  Ravdin, Peter M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGE; BONE DENSITY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EARLY MENOPAUSE; FEMALE; HOSPITALIZATION; HUMAN; METABOLISM; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT;

AGE FACTORS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MENOPAUSE, PREMATURE; OSTEOPOROSIS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; TAMOXIFEN;

EID: 16644368376     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kanis JA, Johnell O, De Laet C, et al: International variations in hip fracture probabilities: Implications for risk assessment. J Bone Miner Res 17:1237-1244, 2002.
2. Stat Bite: Lifetime risk of being diagnosed with breast cancer. J Natl Cancer Inst 95:1745, 2003.
3. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18:1570-1593, 2000.
4. Hodgson SF, Watts NB, Bilezikian JP, et al: American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293-312, 2001.
5. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis: Available at www.nof.org. Accessed 8/25/04.
6. Brown JP, Josse RG: 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 suppl):S1-S34, 2002.
7. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
8. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001.
9. Fogelman I, Blake GM, Blarney R, et al: Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Osteoporos Int 14:1001-1006, 2003.
10. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
11. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003.
12. Fisher B, Costantino JP, Wickerham DL: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998.
13. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003.
14. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996.
15. Love RR, Mazess RB, Barden HS, et al: Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
16. Bissett D, Davis JA, George WD: Gynaecological monitoring during tamoxifen therapy. Lancet 344:1244, 1994.
17. Cutuli B, Petit J, Flicker J: Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: Occurrence of thromboembolic complications. Oncol Rep 1:59-63, 1994.
18. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998.
19. Meier CR, Jick H: Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612, 1998.
20. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996.
21. Twiss JJ, Waltman N, Ott CD, et al: Bone mineral density in postmenopausal breast cancer survivors. J Am Acad Nurse Pract 13:276-284, 2001.
22. Greep NC, Giuliano AE, Hansen NM, et al: The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114:653-659, 2003.
23. Kanis JA, Johnell O, Black DM, et al: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaulation trial. Bone 33:293-300, 2003.
24. Kanis JA, Johnell O, Oden A, et al: Long-term risk of osteoporotic fracture in Malmo. Osteoporosis Int 11:669-674, 2000.
25. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936, 2002.
26. World Health Organisation Technical Report Series 843: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland; World Health Organisation, 1994.
27. Delmas PD: Osteoporosis IV. Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026, 2002.
28. Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082, 1998.
29. McClung MR, Geusens P, Miller PD, et al: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340, 2001.
30. Fleish H: Bisphosphonates: Mechanisms of action. J Clin Endocrinol Metab 19:80-100, 1998.
31. Fosamax prescribing information. Available at www.merck.com/product/usa/ pir̂culars/f/fosamax/fosamax_pi.pdf. Accessed 8/25/04.
32. Actonel (risedronate) prescribing information. Available at www.pgpharma.com/pi/US-Actonel.pdf. Accessed 8/25/04.
33. Cranney A, Waldegger L, Zytaruk N, et al: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 4.CD004523, 2003.
34. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997.
35. Saarto T, Blomqvist C, Valimaki M, et al: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75:602-605, 1997.
36. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333, 2002.
37. Pritchard KI: Hormone replacement in women with a history of breast cancer. Oncologist 6:353-362, 2001.
38. Holmberg L. Anderson H: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison: Trial stopped. Lancet 363:453-455, 2004.
39. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125-134, 2001.
40. Martens MG: Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. J Reprod Med 48:425-434, 2003.
41. O'Regan RM, Gajdos C, Dardes RC, et al: Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94:274-283, 2002.
42. Gnant M, Hausmaninger H, Samonigg H, et al: Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer. Results of a randomized multicenter trial (abstract 12). Breast Cancer Res Treat 76:S31, 2002.
43. Barrett JA. Baron JA. Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporosis Int 14:889-894, 2003.